Seven FDA letters: five cite the sellers' own product pages as evidence
ON THIS PAGE
Key findings
- On April 7, 2026 the FDA posted seven warning letters to online peptide sellers, all dated March 31, 2026, all from the Center for Drug Evaluation and Research.
- Five of the seven sites carried "research use only" or "not for human consumption" labeling. In those five the agency held that the site's own marketing established intended human use and the disclaimer did not counter it. The other two were eBay storefronts making overt disease and body-composition claims with no such disclaimer at all.
- Coded product names did not prevent identification. The letters map catalog codes such as "GLP-2 TRZ" and "GLP-3 RT" to tirzepatide and retatrutide.
- In the five research-storefront letters, offering bacteriostatic water for sale next to the injectable peptides made the water itself an unapproved drug. The compounds were cited separately, on the strength of their own product copy.
Regulators usually move one case at a time. Seven warning letters carrying the same date and posted in the same batch are something else: a statement about a market. The recipients were Gram Peptides, Lovega LLC dba Pink Pony Peptides, Prime Sciences, Mile High Compounds, PekCura Labs, Guangzhou Huli Technology dba Fantasy Face, and FormPour. Reading all seven against each other shows a common theory in most of them and two storefronts that never needed the theory at all.
What the five research letters turn on
Not the compounds as such, and not the disclaimers. Five of the letters, to Gram Peptides, Pink Pony, Prime Sciences, Mile High Compounds, and PekCura Labs, turn on the distance between a label that says research and a product page that describes what the material does to a person. Each of those five quotes the seller's own research-only language back at it, then holds that the website evidence establishes the products are intended for human use anyway. Gram Peptides is typical: the FDA notes the labeling marketed the products for "Research Use Only," and "not intended for human consumption, medical use, or veterinary use," and then sets that aside on the strength of the product pages.
The bacteriostatic water holding
The most-cited detail in secondhand write-ups is also the one most often described backwards. The bundling language in these letters is not evidence about the peptides. It is what reclassifies the water. Each of the five research storefronts sold bacteriostatic water beside the injectable compounds, and the agency treated that pairing as intent for the water. From the Gram Peptides letter:
Your firm offers "Bacteriostatic Water for Injection" for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the two above-mentioned GLP products. The sale of these products together demonstrates that you intend for your "Bacteriostatic Water for Injection" to be used in combination for injection. Therefore, your "Bacteriostatic Water for Injection" is a drug.
The Pink Pony letter reaches the same conclusion in the same words about its "Bacteriostatic Water." The compounds in these letters were not incriminated by what they were sold next to. They were incriminated by their own product copy. The water was the item the bundling argument was built to catch.
Where the pattern breaks
Two of the seven do not fit the research-storefront frame, and a reading that calls the batch uniform misses them. The Fantasy Face letter, to Guangzhou Huli Technology, concerns an eBay listing for a "Googeer GLP-1 Weight Control Oral Solution" and quotes marketing such as "Ideal Body Shaping helps to shape a slim body." The FormPour letter, also an eBay storefront, concerns a microneedle patch and quotes overt disease and body-composition claims from the listing. Neither letter references a research-only disclaimer, because neither storefront carried one, and neither involves bacteriostatic water. These are ordinary overt-claim cases. They belong in the count of seven, but not in the account of the theory that makes the other five interesting.
What generalizes beyond the seven
Two points travel past the specific recipients. Coded catalog names were decoded: the letters connect internal product codes to the compounds they stand for, so a naming layer is not a compliance layer. And in the five research letters, a research label on the compounds did not protect the accessory sold next to them; the shared checkout was enough to pull the bacteriostatic water into drug status on its own.
The enforcement did not stop in April
This was a batch, not the end of one. On June 17, 2026 the FDA posted a further letter to Wholesale Peptide over "Prostamax" and "Gonadorelin," which is verified against the primary document below. A later group of five letters, all dated August 24, 2026 and all posted September 1, 2026, went to Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides. All five have now been read against their primary documents. The earlier version of this piece described them as letters over versions of retatrutide; that was too narrow. The trade report that prompted the check led with retatrutide but also named semaglutide, tesamorelin, elamipretide and bremelanotide; it did not mention tirzepatide or the bacteriostatic water holding. All five name semaglutide, retatrutide, tesamorelin and PT-141. Four of the five cite a bacteriostatic water product; the Royal Peptides letter mentions water only alongside a peptide guide and calculator, not as a cited product. Coded catalog names appear across the group, decoded to different degrees. The agency decodes TXP Innovations' "GLP-1 SEM," "GLP-2 TRZ" and "GLP-3 RT" as semaglutide, tirzepatide and retatrutide, and Peak Performance's "GLP-3R" as retatrutide. NuScience is cited for "GLP-1 Sema Research Peptide," "GLP-2 Tirz Peptide" and "GLP-3 RT (Retatrutide) Research Peptide"; only the last carries its own decode in that letter, and the letter never states what "GLP-2 Tirz" is. The catalogs are not identical. Tirzepatide is named in three of the five, Royal Peptides, Peptide Partners and TXP Innovations; NuScience's letter cites the "GLP-2 Tirz Peptide" it does not decode, and the Peak Performance letter does not name it. SS-31 (elamipretide) is in a different four, absent from NuScience. The NuScience letter alone adds survodutide and mazdutide; the Royal Peptides letter alone adds bimorelin. All five run the same reading as the March 31 batch: each quotes the storefront's own research-use-only labeling and its disclaimer against human use or consumption, in wording that differs letter to letter, and each then holds that "evidence obtained from your website establishes that your products are intended to be drugs for human use." All five also find that the seller supplied "the means to prepare an injectable drug for human administration," but the item said to supply it differs. In the Peak Performance, Peptide Partners and TXP Innovations letters it is the bacteriostatic water marketed as a solvent for reconstituting the products. In the NuScience and Royal Peptides letters the agency points to the water marketed alongside a peptide calculator, and at Royal a peptide guide as well; Royal's letter cites no water product at all. A piece scoped to March 31 should say plainly that the line of enforcement it describes has continued.
What this means for reading vendors
For a buyer evaluating suppliers, the letters sharpen an existing signal. Human-use marketing on a research storefront was always a red flag for seriousness; it is now also a documented enforcement trigger, which makes it a continuity risk. A storefront can be commercially dead within weeks of a letter while its website keeps taking orders, which is the failure mode described in how vendors disappear. The screening machine behind the vendor check flags human-use marketing language for exactly this reason.
Sources
The seven March 31, 2026 warning letters, at fda.gov, each read on 2026-09-02: Gram Peptides, 721806; Lovega LLC dba Pink Pony Peptides, 721088; Prime Sciences, 721805; Mile High Compounds LLC, 721600; PekCura Labs, 721709; Guangzhou Huli Technology Co., Ltd. dba Fantasy Face, 722228; FormPour, 722215. The later action cited above: Wholesale Peptide, 729447, dated June 17, 2026, read 2026-09-02; NuScience Peptides LLC, 733652, dated August 24, 2026, posted September 1, 2026, read 2026-09-02; The four remaining letters of that group, each dated August 24, 2026, each posted September 1, 2026, each read 2026-09-02: Peak Performance Peptides, 735127; Royal Peptides LLC, 734884; Peptide Partners LLC, 735063; TXP Innovations LLC dba Tex Peptides, 735067. Independent corroboration of the April batch: Regulatory Focus, the news arm of the Regulatory Affairs Professionals Society, dated April 7, 2026, which names the same seven recipients (read 2026-09-02); and Pharmaceutical Technology, dated September 2, 2026, which first reported the later five-letter group (read 2026-09-02); that report is retained here as the lead that prompted the check, not as the basis for the account above, which rests on the five letters themselves.
Email updates
New articles and news by email, at most once a day or once a week, whichever you pick.
Respond to this analysis
Corrections, contradictions, and anything you have seen yourself. Responses are read and checked. Verified ones become entries in the ledger or corrections to this page. Nothing posts unverified, and no response is published with anything but the handle you type, or the display name of the account you sign in with. Reporting an error, or asking for this article to come down? Use the Report form below.
Report an error or request a takedown
Reports go to the site's administrators. Nothing is removed automatically.